Adverum Climbs Out Of Abyss With Promising Early Gene Therapy Data In Wet AMD

Feb 08 2024

• By Alaric DeArment

Listen to this article

The Phase II LUNA study of ixo-vec showed a reduction in anti-VEGF use and stabilization of visual acuity and anatomic parameters that Adverum – and some analysts – called best in class.

• Source: Shutterstock

Preliminary Phase II data in wet age-related macular degeneration (wet AMD) give a leg up to Adverum Biotechnologies, Inc.’s ixoberogene soroparvovec (ixo-vec), its gene therapy for retinal diseases, as it looks set to compete closely with two rivals. The positive data were particularly important, coming after the company had to abandon the diabetic macular edema (DME) indication and restructure to focus on wet AMD.

The Redwood City, CA-based biotech presented the preliminary data from the LUNA study on 8 February at the Macula Society’s...

More from Sensory

Sponsored By
Nancy Tests SPARC-931 Part 8
This is a short description. This is a short description.
Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch
Mar 10 2025
• By Alexandra Shimmings
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Acelyrin Belatedly Drops Izokibep In Its Lead Indications
Aug 15 2024
• By Elizabeth Cairns
The group has stopped further development of the IL-17A inhibitor in hidradenitis suppurativa and psoriatic arthritis, and intends to pivot to a thyroid eye disease therapy.
Aldeyra Readies Reproxalap For Dry Eye Refiling After Chamber Study Success
Aug 08 2024
• By Mandy Jackson
The company said earlier this year that it would resubmit reproxalap for US FDA approval before the end of 2024 once it completed another Phase III trial and is eyeing both acute and chronic use.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.